Retatrutide: Recent Clinical Trials and Data (2026 Update)
Fact Checked By
Dr. Alistair J. Vance, PhDSenior Research Fellow, Peptide Synthesis & Metabolic Pathways · PhD Biochemistry
⚠ DISCLAIMER: All products sold by PeptidesUK Healthcare are strictly for laboratory and scientific research purposes only. They are not for human consumption, therapeutic use, or any other application outside of controlled laboratory settings. Researchers must comply with all applicable local, national, and institutional regulations.
Retatrutide (LY3437943), Eli Lilly's investigational triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, has delivered some of the strongest weight loss results seen in metabolic research to date. Early Phase 2 data already showed up to 24% body weight reduction, and recent Phase 3 readouts from the TRIUMPH programme in 2025–2026 have further strengthened its position as a major compound of interest.
This article reviews retatrutide's mechanism, key trial results, safety profile, and implications for ongoing research.
Mechanism of Action
Retatrutide is a single 39-amino acid peptide designed to simultaneously activate three receptors:
- Glucose-dependent insulinotropic polypeptide (GIP)
- Glucagon-like peptide-1 (GLP-1)
- Glucagon
This triple-agonist approach aims to combine the appetite-suppressing and insulin-sensitising effects of GLP-1 and GIP with glucagon's ability to increase energy expenditure and promote lipolysis.
The peptide features a fatty acid chain that extends its half-life, allowing once-weekly dosing in research settings. Its balanced receptor activation profile appears to produce synergistic effects on both caloric intake and energy output.
Phase 2 Trial Results
The foundational Phase 2 study, published in the New England Journal of Medicine, evaluated retatrutide in adults with obesity. Participants receiving the highest dose (12 mg) achieved an average weight loss of 24.2% after 48 weeks, with weight loss still continuing at the end of the trial period.
Notably, 83% of participants on the 12 mg dose lost at least 15% of their body weight. The trial also demonstrated meaningful improvements in cardiometabolic markers including blood pressure, lipids, and HbA1c.
Recent Phase 3 Data (2025–2026)
TRIUMPH-4 (December 2025)
In participants with obesity and knee osteoarthritis, retatrutide 12 mg produced an average weight reduction of 28.7% at 68 weeks — one of the highest figures reported in any anti-obesity medication trial. The study also met its co-primary endpoint of significant knee pain reduction.
TRANSCEND-T2D-1 (March 2026)
This trial in people with type 2 diabetes showed average weight loss of up to 16.8% and HbA1c reductions of up to 2.0% at 40 weeks.
Additional Phase 3 trials examining cardiovascular outcomes and direct comparisons with tirzepatide are expected to report throughout 2026.
Safety Profile
The most common side effects remain gastrointestinal (nausea, vomiting, diarrhoea, constipation), which are generally dose-dependent and improve with slower dose escalation. Transient increases in heart rate have also been observed, consistent with glucagon receptor activation. Long-term safety data from the full TRIUMPH programme will be important as more Phase 3 results become available.
Research Implications
Retatrutide offers researchers a powerful new tool to study the combined effects of GIP, GLP-1, and glucagon receptor signalling. Its ability to drive substantial weight loss while affecting both appetite and energy expenditure makes it valuable for research into severe obesity, MASLD, and cardiometabolic disease.
For laboratory studies, having access to high-purity, batch-tested material with full Certificates of Analysis is essential for reproducible results.
The recent Phase 3 data for retatrutide has reinforced its potential as one of the most efficacious compounds currently being studied in metabolic research. As further trial results emerge throughout 2026, retatrutide is likely to remain a major focus for researchers investigating obesity, diabetes, and related metabolic conditions.
Researchers interested in studying this compound should ensure they are using independently tested, high-purity material with full documentation.
References
- Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
- Eli Lilly and Company. (2025). TRIUMPH-4 Phase 3 Trial Topline Results.
- Eli Lilly and Company. (2026). TRANSCEND-T2D-1 Phase 3 Trial Topline Results.
© PeptidesUK Healthcare — Elara Healthcare Limited. All products for laboratory research use only.
Dr. A. Richardson
Chief Scientific Officer, BSc (Hons) Biochemistry, PhD Peptide Chemistry
Dr. Richardson holds a PhD in Peptide Chemistry from the University of Edinburgh and has over 15 years of experience in peptide synthesis and quality assurance research.
View credentialsThis article is for informational purposes only and does not constitute medical advice. All referenced products are for laboratory research use only.
